An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance

被引:4
|
作者
Micallef, Benjamin [1 ]
Dogne, Jean-Michel [2 ]
Sultana, Janet [3 ]
Straus, Sabine M. J. M. [4 ]
Nistico, Robert [5 ]
Serracino-Inglott, Anthony [1 ,6 ]
Borg, John-Joseph [1 ,5 ]
机构
[1] Med Author, Sir Temi Zammit Bldg,Malta Life Sci Pk, San Gwann SGN 3000, Malta
[2] Univ Namur, Rue Bruxelles 61, B-5000 Namur, Belgium
[3] Univ Exeter, Coll Med & Hlth, Exeter, England
[4] Med Evaluat Board, Utrecht, Netherlands
[5] Univ Tor Vergata, Sch Pharm, Dept Biol, Rome, Italy
[6] Univ Malta, Dept Pharm, Msida, Malta
关键词
ADVERSE DRUG-REACTIONS; DISPROPORTIONALITY ANALYSIS; COMPETITION BIAS; PHARMACOVIGILANCE; SYSTEMS;
D O I
10.1007/s40264-023-01346-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionDuring the signal detection process, statistical methods are used to identify drug-event combinations (DECs) which are disproportionately reported when compared with other drugs and events in the entire database. We hypothesise that the high volume of COVID-19 vaccine adverse drug reaction (ADR) reports transmitted to EudraVigilance may have affected the performance of disproportionality statistics used in routine signal detection, potentially resulting in signals either being masked, or false associations being flagged as potential signals.ObjectiveOur aim was to study the impact of COVID-19 vaccine spontaneous reporting on statistical signal detection in EudraVigilance.MethodsWe recalculated the reporting odds ratio (ROR) for signals that were previously discussed at the level of the Pharmacovigilance Risk Assessment Committee, or signals that were retrieved from EudraVigilance, by omitting COVID-19 vaccine reports from the standard ROR calculation and then comparing the lower confidence interval (LCI) of the recalculated ROR to the LCI of the actual ROR in EudraVigilance.ResultsIn total, 52 signals for 38 active substances were reviewed. For 35 signals, the LCI of the recalculated ROR value was lower than the LCI of the actual ROR (suggesting that COVID-19 vaccine ADR reporting had a positive effect on the strength of the signal) while for 15 signals the LCI of the recalculated ROR value was higher than the LCI of the actual ROR (suggesting that COVID-19 vaccine ADR reporting had an attenuating effect on the strength of the signal). For two signals, no change in the ROR was observed. In our analysis, six significant results were found. Five DECs were found to be masked: bleomycin and immune thrombocytopenia (actual ROR LCI = 0.94, recalculated ROR LCI = 1.02), vortioxetine and heavy menstrual bleeding (actual ROR LCI = 0.3, recalculated ROR LCI = 1.06), caplacizumab and heavy menstrual bleeding (actual ROR LCI = 0.98, recalculated ROR LCI = 3.47), ziprasidone and amenorrhoea (actual ROR LCI = 0.84, recalculated ROR LCI = 1.67), and azacitidine and pericarditis (actual ROR LCI = 0.81, recalculated ROR LCI = 2.01). For the DEC of adalimumab and immune reconstitution inflammatory syndrome, the LCI of the actual ROR value was 1.14 and removing COVID-19 vaccine reporting resulted in an LCI of the recalculated ROR value of 0.94 (below threshold).ConclusionsWe demonstrated five cases of masking and one case of false-positive association due to the influence of COVID-19 vaccine spontaneous reporting on the ROR. This suggests that the high number of adverse drug reaction reports for COVID-19 vaccines in EudraVigilance has the potential to affect routine statistical signal detection activities. The impact of COVID-19 vaccine ADR reports on current signal detection practices requires further evaluation and solutions to tackle masking issues in EudraVigilance may need to be developed.
引用
收藏
页码:1089 / 1103
页数:15
相关论文
共 50 条
  • [1] An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance
    Benjamin Micallef
    Jean-Michel Dogné
    Janet Sultana
    Sabine M. J. M. Straus
    Robert Nisticò
    Anthony Serracino-Inglott
    John-Joseph Borg
    [J]. Drug Safety, 2023, 46 : 1089 - 1103
  • [2] Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events
    Montes-Grajales, Diana
    Garcia-Serna, Ricard
    Mestres, Jordi
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [3] Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events
    Diana Montes-Grajales
    Ricard Garcia-Serna
    Jordi Mestres
    [J]. Scientific Reports, 13
  • [4] Capillary Leak Syndrome and COVID-19 Vaccines: An Analysis of the European Spontaneous Reporting System EudraVigilance
    Napoli, R. D.
    Ruggiero, R.
    Balzano, N.
    Mascolo, A.
    Rafaniello, C.
    Liberata, S.
    Rossi, F.
    Annalisa, C.
    [J]. DRUG SAFETY, 2022, 45 (10) : 1209 - 1209
  • [5] COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance
    Gordillo-Maranon, Maria
    Szmigiel, Agnieszka
    Yalmanova, Vladimira
    Caplanusi, Irina
    Genov, Georgy
    Olsen, David Benee
    Straus, Sabine
    [J]. DRUG SAFETY, 2024, 47 (08) : 783 - 798
  • [6] Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France
    Sibylle de Germay
    Allison Singier
    Francesco Salvo
    Antoine Pariente
    [J]. Drug Safety, 2023, 46 : 1381 - 1389
  • [7] Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France
    de Germay, Sibylle
    Singier, Allison
    Salvo, Francesco
    Pariente, Antoine
    French Pharmacovigilance Network
    [J]. DRUG SAFETY, 2023, 46 (12) : 1381 - 1389
  • [8] Impact of COVID-19 vaccination on pharmacovigilance spontaneous reporting in France
    De Germay, S.
    Singier, A.
    Salvo, F.
    Pariente, A.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 18 - 19
  • [10] An exploratory study of the impact of COVID-19 on foster parenting
    Hanlon, Ryan
    Kim, JaeRan
    Woo, Cossette
    Day, Angelique
    Vanderwill, Lori
    Dallimore, Elise
    [J]. CHILD & FAMILY SOCIAL WORK, 2022, 27 (03) : 371 - 380